Drug Security Forum

The drug assistance system for patients entitled to government support is currently lacking, with regional inequality in drug supply, a lack of brand choice, inappropriate expenditure of monetary benefits, duplication of benefit registers, and monitoring of treatment effectiveness all remaining problem areas. A development strategy for the pharma industry that is based on drug security principles must take into account the evolution of the drug supply system. Any efforts to modernize the existing system for benefit-entitled citizens and other groups of patients with serious diseases must be built on principles of improving its intrinsic tools and its ability to be integrated into a system featuring any model of drug supply, be it drug reimbursement, elements of co-pay, or anything else. The strategy must enable more citizens to be able to count on social preferences, expand the outpatient list of drugs, increase the preventive role of the outpatient sector, and stimulate investment in the pharma industry. What assumptions and objective factors form the basis of the current drug supply system? What tools will help better supply drugs to patients qualifying for benefits? What criteria define economic models of drug reimbursement that are most acceptable to Russia, and what models of full or partial reimbursement of drug costs may be the most effective? Is the Russian Federation ready for universal outpatient drug supply?

Moderator
Aleksandr Petrov, Head of the Subcommittee on Circulation of Medicines, Development of the Pharmaceutical and Medical Industry, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection

Aleksandr Petrov

Head of the Subcommittee on Circulation of Medicines, Development of the Pharmaceutical and Medical Industry, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection

Panellists
Natasha Azzopardi-Muscat, Director, Division of Country Health Policies and Systems, Regional Office for Europe, World Health Organization (online)
Elena Astapenko, Director, Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices, Ministry of Health of the Russian Federation
Alisa Dzhangiryants, Director of Market Access and Pricing, Bristol-Myers Squibb (online)
Gilles Carbonnier, Vice President, International Committee of the Red Cross
Natalia Kolerova, President, Novartis Group in Russia; General Manager, Oncology Department, Russia, Ukraine and CIS, Novartis AG
Timofey Nizhegorodtsev, Deputy Head, Federal Antimonopoly Service of the Russian Federation
Ekaterina Pogodina, Director General, Managing Director of Janssen Pharmaceutical Companies, Johnson & Johnson Russia & CIS
Elena Chernyakova, Chairman, Federal Compulsory Medical Insurance Fund

Elena Astapenko

Director, Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices, Ministry of Health of the Russian Federation

Gilles Carbonnier

Vice President, International Committee of the Red Cross

Mr Carbonnier has been professor of development economics at the Graduate Institute of International and Development Studies since 2007, where he also served as Director of Studies and President of the Centre for Education and Research in Humanitarian Action. His expertise focuses on international development cooperation, the economic dynamics of armed conflict, and the nexus between natural resources and development. His latest book, published by Hurst and Oxford University Press in 2016, is entitled Humanitarian Economics. War, Disaster and the Global Aid Market.
Prior to joining the Graduate Institute, Gilles Carbonnier worked with the ICRC in Iraq, Ethiopia, El Salvador and Sri Lanka (1989-91), and served as economic adviser at ICRC headquarters (1999-2006). Between 1992 and 1996, he was in charge of international trade negotiations and development cooperation programmes with the Swiss Federal Department of Economy.

Natalia Kolerova

President, Novartis Group in Russia; General Manager, Oncology Department, Russia, Ukraine and CIS, Novartis AG

Natalia Kolerova was appointed Country President of Novartis Group Russia in September 2019. Since 2014 Natalia has been the General Manager of the Oncology business division of the company and continues to execute these responsibilities following her appointment.
Natalia joined Novartis in 2008 as the Head of the Specialties Business unit. Subsequently, Natalia served as the Head of the Market Access function and was responsible for ensuring the availability of drugs in the oncological portfolio of the company at the federal and regional levels.
Prior to joining Novartis, Natalia held senior positions in the Russian offices of the international pharmaceutical companies Abbott Lababorats (Abbott Lab SA) and Sanofi-Aventis (Sanofi-Aventis).
Natalia graduated from the I.M. Sechenov First Moscow State Medical University majoring in Pharmacy, as well as Lomonosov Moscow State University, majoring in Sociology. Natalia also holds a MBA degree.

Timofey Nizhegorodtsev

Deputy Head, Federal Antimonopoly Service of the Russian Federation

In 1997, Timofey Nizhegorodtsev graduated from the Biology Department of Irkutsk State University. In 2009, he received a Master of Jurisprudence degree from the Russian Academy of State Service under the President of the Russian Federation.
At the Federal Antimonopoly Service of Russia, he is engaged in the development of competition in the social sphere and trade. With his direct involvement, a system of public and expert advisory councils under the FAS Russia was created. A number of action plans and packages of amendments to the regulatory legal acts for the development of competition in such spheres as health care and trade, tourism and education, as well as in the sphere of ritual services have been prepared. These include the Law on Trade (2009) and amendments to it (2016), the Law on Education (2012), the Law on Compulsory Health Insurance (2010), as well as amendments to the Law on Tourist Activities, the Law on Public Health Protection (2010) and the Law on Circulation of Medicines.
Timofey Nizhegorodtsev contributed greatly to the tariff regulation in the field of circulation of medicines. In particular, in 2018, new rules for state registration and re-registration of maximum selling prices for drugs included in the list of VEDs were developed and approved by Government Decree No. 1207, as well as a methodology for calculating such prices. In addition, with his participation legislation on the interchangeability of medicines was prepared (2014, 2019).
He was also actively involved in the development of "antimonopoly packages".
In 2007, Timofey Nizhegorodtsev headed the Department of the social sphere and trade of the Federal Antimonopoly Service of Russia.
In 2018, the work of the Department of Control of the Social Sphere and Trade in the field of competition advocacy was highly appreciated at the international level. The regulatory act developed by the Department, which brought transparency to the specifics of the description of medicines for medical use that are procured by the state, won in the category "Creating Markets for Private Sector Development" and thus for the first time brought FAS Russia 1st place in the World Bank-ICC international competition on competition advocacy.
In 2013, he was awarded the Medal of the Order "For Merit to the Fatherland" II degree, in 2017 - the Medal of the Order "For Merit to the Fatherland" I degree.
In 2011, he was awarded the title "Honorary Worker of the Antimonopoly Agencies of Russia".
In 2015, he was awarded the Badge of Honor of the Federal Antimonopoly Service "For Merits in the Development of Competition in Russia".
In 2019, he was awarded the Medal of the Federal Antimonopoly Service "For Distinction in Service" III degree.
In 2019, he was awarded the medal "For Contribution to the Development of the Eurasian Economic Union".
As Deputy Head of the Federal Antimonopoly Service of Russia, Timofey Nizhegorodtsev supervises health care, social sphere, trade and non-productive services.

Ekaterina Pogodina

Director General, Managing Director of Janssen Pharmaceutical Companies, Johnson & Johnson Russia & CIS

Katerina began her career with Janssen in 2001, holding a number of positions in the Sales, Marketing and Market Access teams. She has been a member of the Russian board of directors since 2010 and was appointed Country Manager Russia in 2015, and then she was promoted to the position of Managing Director Russia & CIS in 2017. In April 2019 Katerina was appointed CEO of Johnson & Johnson Russia & CIS.
Throughout her 17-year career with Janssen, Katerina has consistently demonstrated high standards of quality and strong results. She led the launch of a whole range of new products and work across a number of therapeutic areas, as well as establishing several new business units. In her role as Commercial Operations Director, Russia, Katerina successfully led commercial teams in close collaboration with other departments, which yielded great business results and drove the company’s overall success.
Katerina graduated with distinction from the International University in Moscow, where she studied law. She also completed specialist education for senior executives at the London School of Economics and Political Science and Moscow School of Management Skolkovo.
Since 2015 Katerina has been a member of the board of directors of the Association of International Pharmaceutical Manufacturers (AIPM). Forbes magazine contributor, speaker of the Second Eurasian Women’s Forum.

Elena Chernyakova

Chairman, Federal Compulsory Medical Insurance Fund

Born on December 21, 1969 in the city of Kazan.

In 1997, she graduated from the Moscow State University of Commerce.
In 1991-1995 she worked as economist, accountant, chief accountant of production units of KAMAZ JSC.
In 1995-2001 she held the posts of deputy chief accountant, head of service, chief accountant of the Industrial Housing Maintenance Department of the city of Naberezhnye Chelny.
In 2001-2011, she was Deputy Chief Accountant of the Department of the Ministry of Construction, Architecture and Architecture of the Russian Federation. - From 2001 to 2011, she was Head of Department of the Ministry of Construction, Architecture and Housing and Communal Services of the Republic of Tatarstan, then Deputy Director of the Center for Economic and Social Research under the Cabinet of Ministers of the Republic.
In March 2011 she was appointed Deputy Director of the Department of Budget Policy and Methodology of the Ministry of Finance of the Russian Federation.
From 2011, she was Director of the Department of Information Resources of the Russian Ministry of Finance, then she headed the Department of Information Technology in the management of state and municipal finances and information support of the budget process of the Russian Ministry of Finance.
On March 13, 2020, she was appointed Chairperson of the Federal Compulsory Medical Insurance Fund, in accordance with Decree No. 600-r of the Government of the Russian Federation of March 13, 2020.
E. Chernyakova has the class rank of Acting State Counsellor of the Russian Federation, 3rd Class.
Awarded a medal of the Order "For Merit to the Fatherland" II degree. Holds a commendation from the President of the Russian Federation and the Minister of Finance of the Russian Federation. Also awarded with the Certificate of Merit of the President of the Russian Federation, the Certificate of Merit of the General Prosecutor of the Russian Federation, and the Medal "For Assistance to the Federal Tax Service" of the Federal Tax Service.
Holds a number of awards from federal and regional authorities of the Russian Federation.
Honored Economist of the Republic of Tatarstan.

Front row participant
Dmitry Kudrumov, First Deputy Chairman of the Government of Kirov Region

Dmitry Kudrumov

First Deputy Chairman of the Government of Kirov Region